2527079-60-1
Chemical Structure
Zaltenibart
Synonym(s): OMS906
- CAS No.: 2527079-60-1
- Formula:N/A
- Molecular Weight:(144.437 kDa)
SMILES: [Zaltenibart]
Biological Activity: Zaltenibart (OMS906) is an IgG4 humanized monoclonal antibody and MASP-3 inhibitor. By inhibiting MASP-3, Zaltenibart achieves upstream inhibition of the alternative complement pathway. MASP-3 is an upstream activator of Factor D (Factor D), a key enzyme in the alternative complement pathway. Zaltenibart prevents both intravascular hemolysis and extravascular hemolysis. Zaltenibart is applicable to research related to paroxysmal nocturnal hemoglobinuria[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Zaltenibart | 99% | Zaltenibart (OMS906) is an IgG4 humanized monoclonal antibody and MASP-3 inhibitor. By inhibiting MASP-3, Zaltenibart achieves upstream inhibition of the alternative complement pathway. MASP-3 is an upstream activator of Factor D (Factor D), a key enzyme in the alternative complement pathway. Zaltenibart prevents both intravascular hemolysis and extravascular hemolysis. Zaltenibart is applicable to research related to paroxysmal nocturnal hemoglobinuria. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
[1]. Griffin M, et al. Monotherapy treatment with Zaltenibart (OMS906), an alternative pathway Masp-3 inhibitor, improved key hematologic parameters in patients with PNH with a suboptimal response to Ravulizumab: Interim results from a phase 2 proof-of-concept study. Blood. 2024 Nov 5;144:4072.
- [2]. Kelly RJ, et al. Pharmacological Therapies in Paroxysmal Nocturnal Haemoglobinuria: Focus on Complement Inhibition. Drugs. 2025;85(11):1413-1428. [Content Brief]
Keywords
